Table 3.
Adverse events during and after radiofrequency ablation
| Propofol regimen | Midazolam regimen | P | ||||
|---|---|---|---|---|---|---|
| Any grade | Grade 3 ≤ | Any grade | Grade 3 ≤ | Any grade | Grade 3 ≤ | |
| During radiofrequency ablation [n (%)] | ||||||
| Hypertension | 50 (76.9) | 35 (53.9) | 50 (71.4) | 25 (35.7) | 0.557 | 0.039 |
| Abdominal pain | 10 (15.4) | 0 (0) | 14 (20.0) | 2 (2.9) | 0.509 | 0.497 |
| Nausea | 8 (12.3) | 0 (0) | 8 (11.4) | 0 (0) | 1.000 | — |
| Vomiting | 6 (9.2) | 0 (0) | 5 (7.1) | 0 (0) | 0.758 | — |
| Vasovagal reaction | 2 (3.1) | 2 (3.1) | 4 (5.7) | 4 (5.7) | 0.682 | 0.682 |
| Apnea | 4 (6.2) | 4 (6.2) | 2 (2.9) | 2 (2.9) | 0.428 | 0.428 |
| Intra‐abdominal hemorrhage | 3 (4.6) | 1 (1.5) | 1 (1.5) | 0 (0) | 0.109 | 0.482 |
| After radiofrequency ablation [n (%)] | ||||||
| AST increase | 58 (89.2) | 22 (33.9) | 60 (85.7) | 25 (35.7) | 0.610 | 0.858 |
| Hypoalbuminemia | 27 (41.5) | 0 (0) | 36 (51.4) | 0 (0) | 0.301 | |
| Anemia | 25 (38.5) | 2 (3.1) | 33 (47.1) | 0 (0) | 0.385 | 0.230 |
| Blood bilirubin increase | 17 (26.2) | 2 (3.1) | 35 (50.0) | 0 (0) | 0.005 | 0.230 |
| Platelet count decrease | 22 (33.9) | 6 (9.2) | 22 (31.4) | 5 (7.1) | 0.855 | 0.758 |
| White blood cell decrease | 9 (13.9) | 2 (3.1) | 10 (14.3) | 0 (0) | 1.000 | 0.230 |
| Anorexia | 10 (15.4) | 0 (0) | 8 (11.4) | 0 (0) | 0.614 | — |
| Fever | 6 (9.2) | 0 (0) | 8 (11.4) | 0 (0) | 0.781 | — |
| Abdominal pain | 6 (9.2) | 0 (0) | 5 (7.1) | 0 (0) | 0.758 | — |
| Hypertension | 3 (4.6) | 2 (3.1) | 2 (2.9) | 0 (0) | 0.672 | 0.230 |
†
Listed adverse events defined by the National Cancer Institution Common Terminology Criteria (version 4.0).
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY, amylase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transpeptidase.